Head to head
GUBamy against Cagrilintide
Two amylin analogues, one with phase 3 data and one with a single completed phase 1 of 76 people and no published result at all. Weight loss figures circulating for GUBamy could not be traced to a primary source, which is the difference this page exists to show.
Column A
GUBamyGUB014295 (GUBamy), long-acting amylin analogue
A long-acting amylin analogue from Gubra with one completed phase 1 trial of 76 people sponsored by AbbVie. No result from that trial, and no other human or animal data, has been published; PubMed holds zero records for the compound. Weight loss figures circulating for it could not be traced to any primary source.
Column B
CagrilintideCagrilintide (long-acting amylin receptor agonist)
An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Side by side, on the facts we can check
| Attribute | GUBamy | Cagrilintide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Not approved. One completed phase 1 (NCT06144684, 76 participants, sponsor AbbVie) with safety primary outcomes; no results posted, no publications. | Investigational, not FDA-approved |
| Half-life | Not reported | ~7 days |
| Molecular weight | Not reported | ~3,700 Da |
| Mechanism | Amylin acts on receptors formed by the calcitonin receptor paired with receptor activity modifying proteins, in the hindbrain area postrema and elsewhere, to slow gastric emptying, suppress post-meal glucagon secretion and reduce food intake by promoting meal termination. Native amylin aggregates and lasts minutes; long-acting analogues are engineered to resist aggregation and to bind albumin or carry a lipid chain so that they can be dosed weekly. Some agents in the class are selective for amylin receptors and others also activate the calcitonin receptor directly; which GUB014295 is has not been stated in any primary source located for this profile, so it is described only as its trial record describes it, a long-acting amylin analogue. Nothing specific to GUB014295's mechanism, receptor pharmacology, half-life or pharmacodynamics in people or animals has been published. | Agonizes amylin receptors in the hypothalamus and brainstem to promote satiety and delay gastric emptying, complementing GLP-1 signaling. |
| Human studies cited | 1 | 3 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between GUBamy and Cagrilintide?
GUBamy: A long-acting amylin analogue from Gubra with one completed phase 1 trial of 76 people sponsored by AbbVie. No result from that trial, and no other human or animal data, has been published; PubMed holds zero records for the compound. Weight loss figures circulating for it could not be traced to any primary source. Cagrilintide: An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.
Which has stronger research evidence, GUBamy or Cagrilintide?
This database does not grade compounds. It counts what was run in people: 1 of the 4 studies cited on the GUBamy profile were human work, against 3 of 3 for Cagrilintide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are GUBamy and Cagrilintide FDA-approved?
GUBamy: Not approved. One completed phase 1 (NCT06144684, 76 participants, sponsor AbbVie) with safety primary outcomes; no results posted, no publications.. Cagrilintide: Investigational, not FDA-approved.
Related posts
Blog articles that cover GUBamy or Cagrilintide, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.